Predicting the long-term risk of repeat coronary events in patients with unstable angina

Маркова, И. А.; Медведева, Е. А.; Гелис, Л. Г.

doi:10.15829/1560-4071-2013-5-18-22

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В ходе исследования отмечалось, что госпитальные исходы у пациентов, госпитализированных с ИМ, закономерно отличались от аналогичных показателей пациентов с НС. По некоторым данным уровень госпитальной (3-4%) смертности у пациентов с НС не различался, а в некоторых случаях даже превышал таковой при ИМ [9], что не было подтверждено в нашем исследовании.…”

Section: Discussionunclassified

Evaluation of Procalcitonin Levels in Patients with Various Forms of Acute Coronary Syndrome, Depending on the Presence of Adverse Hospital Outcomes

Драпкина¹,

Zakharova²

2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. to study the levels of procalcitonin in patients with various forms of acute coronary syndrome (ACS), depending on the presence of adverse hospital outcomes.Materials and Methods. The study included 222 patients admitted to the emergency cardiology department with a diagnosis of ACS in the period from March 2014. until January 2017. Of these, 106 (47.7 %) patients were diagnosed with unstable angina (NS) and 116 (52.3%) with myocardial infarction (MI). Non ST segment elevation MI (NSTEMI) was diagnosed in 47 (40.5%) patients with MI, and ST elevation MI (STEMI) – in 69 (59.5%) patients with MI. After the assessment of the patient's compliance with the criteria for inclusion/exclusion in the study, the procedure for signing the patient's informed consent form was carried out. The protocol of the study was approved by the local Ethics committee of the M. E. Zhadkevich State Clinical Hospital. In each study subgroup, the presence of adverse outcomes during the current hospitalization was assessed: cardiovascular death, nonfatal MI, nonfatal acute cerebrovascular accident, acute heart failure, as well as a combined endpoint, including all of the listed adverse outcomes. All patients, in addition to routine laboratory methods of investigation, were examined for the level of procalcitonin at admission to the hospital, on 2-3 and 4-5 days.Results. Patients with MI compared to patients with NS were characterized by a large number of registered endpoints in general (24.1% vs. 6.6%, p<0.001), while in the group of patients with MI, cardiovascular death was more often recorded (10.3% vs. 0.9%, p<0.001) and acute heart failure (12.9% vs. 5.6%, p=0.009). Patients with MI, in particular with STEMI, who had adverse hospital outcomes, were characterized by statistically significantly higher levels of procalcitonin compared to patients without adverse hospital outcomes. Patients with STEMI showed significantly higher levels of procalcitonin at all stages of the disease, and patients with MI-only at 2-3 and 4-5 days. There were no statistically significant differences in the level of procalcitonin at all stages of the disease in patients with NSTEMI and with unstable angina, depending on the hospital outcomes.Conclusion. Elevated procalcitonin levels in patients with MI, in particular with STEMI, are associated with adverse hospital outcomes; for other forms of ACS, no statistically significant differences were observed with different hospital outcomes.

show abstract

Section: Discussionunclassified

Evaluation of Procalcitonin Levels in Patients with Various Forms of Acute Coronary Syndrome, Depending on the Presence of Adverse Hospital Outcomes

Драпкина¹,

Zakharova²

2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

Pharmacogenetics of acute coronary syndrome: the role of single nucleotide polymorphisms (literature review)

Ulitina,

Sirotkina,

Vershinina

et al. 2024

jour

View full text Add to dashboard Cite

Cardiovascular diseases are the most common cause of death both in Russia and throughout the world. Acute coronary syndrome (ACS) develops during the coronary heart disease and represents a serious medical and social problem. The effectiveness and safety of pharmacotherapy for ACS can be influenced by the individual genetic characteristics of the patient, primarily single nucleotide polymorphisms (SNPs) of the primary DNA structure. The literature review contains information about the epidemiology of ACS, the nomenclature of SNPs, and the molecular basis of the influence of SNPs on physiological and pathological processes in the human body. The main groups of drugs used for ACS and the main functional groups of proteincoding genes, SNPs of which can modulate an individual’s response to pharmacotherapy, are listed in the review. SNPs of noncoding RNA genes have been characterized as promising objects of study. The review shows concept of multilevel regulation of the interaction between drug and human organism and the role of SNPs in that concept. Detection of SNPs is an important component of studying the pharmacokinetics and pharmacodynamics of drugs, since information about the patient’s genetic status is the basis for a personalized approach to pharmacotherapy.

show abstract

Predicting the long-term risk of repeat coronary events in patients with unstable angina

Cited by 2 publications

References 5 publications

Evaluation of Procalcitonin Levels in Patients with Various Forms of Acute Coronary Syndrome, Depending on the Presence of Adverse Hospital Outcomes

Evaluation of Procalcitonin Levels in Patients with Various Forms of Acute Coronary Syndrome, Depending on the Presence of Adverse Hospital Outcomes

Pharmacogenetics of acute coronary syndrome: the role of single nucleotide polymorphisms (literature review)

Contact Info

Product

Resources

About